Atlas-backed biotech focused on Huntington's disease shuts down less than three years...

cafead

Administrator
Staff member
  • cafead   Oct 12, 2022 at 10:52: AM
via An Atlas-founded biotech quietly shut down this week, with the CEO posting only a short statement on LinkedIn to announce the move.

Triplet Therapeutics is no longer operational, chief exec Nessan Bermingham said on the social media site Tuesday, less than three years after it launched. In December 2019, Triplet debuted with a $59 million Series A, nabbing cash from Atlas, MPM Capital and Pfizer Ventures in an effort to develop antisense drugs for Huntington’s disease.

article source